NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free REGN Stock Alerts $959.92 -4.55 (-0.47%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$959.49▼$970.7150-Day Range$902.69▼$993.3552-Week Range$684.80▼$998.33Volume360,151 shsAverage Volume454,027 shsMarket Capitalization$105.36 billionP/E Ratio27.62Dividend YieldN/APrice Target$959.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.72 Rating ScoreUpside/Downside0.1% Downside$959.09 Price TargetShort InterestHealthy1.24% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.78Based on 21 Articles This WeekInsider TradingSelling Shares$18.48 M Sold Last QuarterProj. Earnings Growth3.72%From $38.75 to $40.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector169th out of 947 stocksPharmaceutical Preparations Industry73rd out of 433 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 19 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $959.09, Regeneron Pharmaceuticals has a forecasted downside of 0.1% from its current price of $959.92.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.24% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 0.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.8 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Regeneron Pharmaceuticals this week, compared to 14 articles on an average week.Search Interest18 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows21 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 91% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,479,805.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.15% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 3.72% in the coming year, from $38.75 to $40.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 27.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 156.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 27.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 253.22.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesMarch 17, 2024 | insidertrades.comAndrew J. Murphy Sells 5,783 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMarch 19, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by BrokeragesMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 18, 2024 | reuters.comUS appeals court revives Regeneron's antitrust lawsuit against NovartisMarch 17, 2024 | finance.yahoo.comRegeneron Pharmaceuticals Insiders Sold US$26m Of Shares Suggesting HesitancyMarch 15, 2024 | ca.finance.yahoo.comREGN Mar 2024 885.000 putMarch 13, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)March 13, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in March 2024March 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 13, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Receives New Coverage from Analysts at Sanford C. BernsteinMarch 12, 2024 | prnewswire.comHigh School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationMarch 12, 2024 | globenewswire.comHigh School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationMarch 12, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)March 12, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference (Transcript)March 11, 2024 | markets.businessinsider.comRegeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8March 11, 2024 | finanznachrichten.deRegeneron Pharmaceuticals, Inc.: Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolMarch 11, 2024 | globenewswire.comPraluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolMarch 9, 2024 | finance.yahoo.comIs There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 42% Undervaluation?March 9, 2024 | fool.comMissed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.March 8, 2024 | fool.com2 Biotech Stocks to Buy Hand Over Fist in MarchMarch 8, 2024 | globenewswire.comEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The LancetMarch 6, 2024 | finance.yahoo.comREGN Apr 2024 980.000 callMarch 6, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) TD Cowen 44th Annual Health Care Conference Call TranscriptMarch 5, 2024 | finance.yahoo.com2seventy bio Inc (TSVT) Reports Mixed Financial Results Amid Strategic Shift and Competitive ...March 4, 2024 | investorplace.comBiotechs on the Rise: 3 Stocks to Buy for a Shot of ProfitsMarch 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their impressive 139% return over the last five yearsMarch 2, 2024 | ca.finance.yahoo.comREGN Mar 2024 1050.000 callSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/02/2024Today3/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$959.09 High Stock Price Target$1,184.00 Low Stock Price Target$680.00 Potential Upside/Downside-0.1%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage25 Analysts Profitability EPS (Most Recent Fiscal Year)$34.75 Trailing P/E Ratio27.62 Forward P/E Ratio24.93 P/E Growth2.78Net Income$3.95 billion Net Margins30.14% Pretax Margin32.01% Return on Equity17.61% Return on Assets13.76% Debt Debt-to-Equity Ratio0.10 Current Ratio5.69 Quick Ratio4.94 Sales & Book Value Annual Sales$13.12 billion Price / Sales8.03 Cash Flow$43.30 per share Price / Cash Flow22.17 Book Value$236.63 per share Price / Book4.06Miscellaneous Outstanding Shares109,760,000Free Float100,070,000Market Cap$105.36 billion OptionableOptionable Beta0.11 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $7MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $6.59MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.62MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $1.95MMs. Marion E. McCourt (Age 64)Executive Vice President of Commercial Comp: $1.5MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXBristol-Myers SquibbNYSE:BMYSanofiNASDAQ:SNYGSKNYSE:GSKZoetisNYSE:ZTSView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 158 shares on 3/15/2024Ownership: 0.001%Andrew J MurphySold 5,783 sharesTotal: $5.53 M ($956.47/share)Sivia Capital Partners LLCBought 271 shares on 3/13/2024Ownership: 0.000%Vanguard Group Inc.Bought 39,780 shares on 3/11/2024Ownership: 8.052%Wahed Invest LLCBought 119 shares on 3/11/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Regeneron Pharmaceuticals was last updated on Sunday, March 17, 2024 at 4:53 PM. Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals has a strong product portfolio, including EYLEA injection for various eye diseases, which has shown significant efficacy in treating these conditions. The company has received positive ratings from Wall Street analysts, with a majority of analysts giving it a "buy" or "outperform" rating, indicating confidence in its growth potential. Recent financial reports show that institutional investors and hedge funds have been increasing their holdings in Regeneron Pharmaceuticals, signaling confidence in the company's future performance. Regeneron Pharmaceuticals has a history of consistent innovation and research in developing new medicines, which could lead to potential breakthrough products in the future. Despite market fluctuations, Regeneron Pharmaceuticals has maintained a stable stock price, indicating resilience and potential for long-term growth. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: Regeneron Pharmaceuticals faces competition from other biopharmaceutical companies in the market, which could impact its market share and revenue growth. The biopharmaceutical industry is subject to regulatory challenges and uncertainties, which could affect the company's ability to bring new products to market and generate revenue. Market analysts have identified potential risks associated with investing in Regeneron Pharmaceuticals, such as market volatility and changes in healthcare policies that could impact the company's financial performance. Investing in biopharmaceutical companies like Regeneron Pharmaceuticals carries inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new products. While Regeneron Pharmaceuticals has shown resilience in its stock price, external factors such as economic conditions and global events could still impact its financial stability and growth prospects. REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 25 Wall Street research analysts have issued 1-year price objectives for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $680.00 to $1,184.00. On average, they predict the company's share price to reach $959.09 in the next year. This suggests that the stock has a possible downside of 0.1%. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2024? Regeneron Pharmaceuticals' stock was trading at $878.29 on January 1st, 2024. Since then, REGN stock has increased by 9.3% and is now trading at $959.92. View the best growth stocks for 2024 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a trailing twelve-month return on equity of 17.61%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the firm earned $10.96 EPS. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), American CenturyFocused Dynamic Growth ETF (FDG) and Subversive Mental Health ETF (SANE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.11%), Vanguard Group Inc. (8.05%), Capital World Investors (4.71%), Capital International Investors (2.68%), Dodge & Cox (2.16%) and Putnam Investments LLC (1.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.